1
|
Yang A, Zhang W, Wang J, Yang K, Han Y, Zhang L. Review on the Application of Machine Learning Algorithms in the Sequence Data Mining of DNA. Front Bioeng Biotechnol 2020; 8:1032. [PMID: 33015010 PMCID: PMC7498545 DOI: 10.3389/fbioe.2020.01032] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Accepted: 08/10/2020] [Indexed: 11/13/2022] Open
Abstract
Deoxyribonucleic acid (DNA) is a biological macromolecule. Its main function is information storage. At present, the advancement of sequencing technology had caused DNA sequence data to grow at an explosive rate, which has also pushed the study of DNA sequences in the wave of big data. Moreover, machine learning is a powerful technique for analyzing largescale data and learns spontaneously to gain knowledge. It has been widely used in DNA sequence data analysis and obtained a lot of research achievements. Firstly, the review introduces the development process of sequencing technology, expounds on the concept of DNA sequence data structure and sequence similarity. Then we analyze the basic process of data mining, summary several major machine learning algorithms, and put forward the challenges faced by machine learning algorithms in the mining of biological sequence data and possible solutions in the future. Then we review four typical applications of machine learning in DNA sequence data: DNA sequence alignment, DNA sequence classification, DNA sequence clustering, and DNA pattern mining. We analyze their corresponding biological application background and significance, and systematically summarized the development and potential problems in the field of DNA sequence data mining in recent years. Finally, we summarize the content of the review and look into the future of some research directions for the next step.
Collapse
Affiliation(s)
- Aimin Yang
- College of Science, North China University of Science and Technology, Tangshan, China
| | - Wei Zhang
- College of Science, North China University of Science and Technology, Tangshan, China
| | - Jiahao Wang
- College of Science, North China University of Science and Technology, Tangshan, China
| | - Ke Yang
- College of Yi Sheng, North China University of Science and Technology, Tangshan, China
| | - Yang Han
- College of Science, North China University of Science and Technology, Tangshan, China
| | - Limin Zhang
- Mathmatics and Computer Department, Hengshui University, Hengshui, China
| |
Collapse
|
2
|
Novak BJ, Fraser D, Maloney TH. Transforming Ocean Conservation: Applying the Genetic Rescue Toolkit. Genes (Basel) 2020; 11:E209. [PMID: 32085502 PMCID: PMC7074136 DOI: 10.3390/genes11020209] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2019] [Revised: 01/25/2020] [Accepted: 02/13/2020] [Indexed: 01/21/2023] Open
Abstract
Although oceans provide critical ecosystem services and support the most abundant populations on earth, the extent of damage impacting oceans and the diversity of strategies to protect them is disconcertingly, and disproportionately, understudied. While conventional modes of conservation have made strides in mitigating impacts of human activities on ocean ecosystems, those strategies alone cannot completely stem the tide of mounting threats. Biotechnology and genomic research should be harnessed and developed within conservation frameworks to foster the persistence of viable ocean ecosystems. This document distills the results of a targeted survey, the Ocean Genomics Horizon Scan, which assessed opportunities to bring novel genetic rescue tools to marine conservation. From this Horizon Scan, we have identified how novel approaches from synthetic biology and genomics can alleviate major marine threats. While ethical frameworks for biotechnological interventions are necessary for effective and responsible practice, here we primarily assessed technological and social factors directly affecting technical development and deployment of biotechnology interventions for marine conservation. Genetic insight can greatly enhance established conservation methods, but the severity of many threats may demand genomic intervention. While intervention is controversial, for many marine areas the cost of inaction is too high to allow controversy to be a barrier to conserving viable ecosystems. Here, we offer a set of recommendations for engagement and program development to deploy genetic rescue safely and responsibly.
Collapse
Affiliation(s)
- Ben J. Novak
- Revive & Restore, 1505 Bridgeway #203, Sausalito, CA 94965, USA;
| | - Devaughn Fraser
- Genetics Research Lab, California Department of Fish and Wildlife, Sacramento, CA 95834, USA;
| | | |
Collapse
|
3
|
Abstract
It is well established that variations in genes can alter the pharmacokinetic and pharmacodynamic profile of a drug and immunological responses to it. Early advances in pharmacogenetics were made with traditional genetic techniques such as functional cloning of genes using knowledge gained from purified proteins, and candidate gene analysis. Over the past decade, techniques for analysing the human genome have accelerated greatly as knowledge and technological capabilities have grown. These techniques were initially focussed on understanding genetic factors of disease, but increasingly they are helping to clarify the genetic basis of variable drug responses and adverse drug reactions (ADRs). We examine genetic methods that have been applied to the understanding of ADRs, review the current state of knowledge of genetic factors that influence ADR development, and discuss how the application of genome-wide association studies and next-generation sequencing approaches is supporting and extending existing knowledge of pharmacogenetic processes leading to ADRs. Such approaches have identified single genes that are major contributing genetic risk factors for an ADR, (such as flucloxacillin and drug-induced liver disease), making pre-treatment testing a possibility. They have contributed to the identification of multiple genetic determinants of a single ADR, some involving both pharmacologic and immunological processes (such as phenytoin and severe cutaneous adverse reactions). They have indicated that rare genetic variants, often not previously reported, are likely to have more influence on the phenotype than common variants that have been traditionally tested for. The problem of genotype/phenotype discordance affecting the interpretation of pharmacogenetic screening and the future of genome-based testing applied to ADRs are also discussed.
Collapse
|
4
|
Dupras C, Ravitsky V. Epigenetics in the Neoliberal "Regime of Truth": A Biopolitical Perspective on Knowledge Translation. Hastings Cent Rep 2015; 46:26-35. [PMID: 26659400 DOI: 10.1002/hast.522] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Recent findings in epigenetics have been attracting much attention from social scientists and bioethicists because they reveal the molecular mechanisms by which exposure to socioenvironmental factors, such as pollutants and social adversity, can influence the expression of genes throughout life. Most surprisingly, some epigenetic modifications may also be heritable via germ cells across generations. Epigenetics may be the missing molecular evidence of the importance of using preventive strategies at the policy level to reduce the incidence and prevalence of common diseases. But while this "policy translation" of epigenetics introduces new arguments in favor of public health strategies and policy-making, a more "clinical translation" of epigenetics is also emerging. It focuses on the biochemical mechanisms and epigenetic variants at the origin of disease, leading to novel biomedical means of assessing epigenetic susceptibility and reversing detrimental epigenetic variants. In this paper, we argue that the impetus to create new biomedical interventions to manipulate and reverse epigenetic variants is likely to garner more attention than effective social and public health interventions and therefore also to garner a greater share of limited public resources. This is likely to happen because of the current biopolitical context in which scientific findings are translated. This contemporary neoliberal "regime of truth," to use a term from Michel Foucault, greatly influences the ways in which knowledge is being interpreted and implemented. Building on sociologist Thomas Lemke's Foucauldian "analytics of biopolitics" and on literature from the field of science and technology studies, we present two sociological trends that may impede the policy translation of epigenetics: molecularization and biomedicalization. These trends, we argue, are likely to favor the clinical translation of epigenetics-in other words, the development of new clinical tools fostering what has been called "personalized" or "precision" medicine. In addition, we argue that an overemphasized clinical translation of epigenetics may further reinforce this biopolitical landscape through four processes closely related to neoliberal pathways of thinking: the internalization and isolation (aspects of liberal individualism) of socioenvironmental determinants of health and increased opportunities for commodification and technologicalization (aspects of economic liberalism) of health care interventions.
Collapse
|
5
|
Lukovic D, Moreno-Manzano V, Klabusay M, Stojkovic M, Bhattacharya SS, Erceg S. Non-coding RNAs in pluripotency and neural differentiation of human pluripotent stem cells. Front Genet 2014; 5:132. [PMID: 24860598 PMCID: PMC4030195 DOI: 10.3389/fgene.2014.00132] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Accepted: 04/24/2014] [Indexed: 12/20/2022] Open
Abstract
Several studies have demonstrated the important role of non-coding RNAs as regulators of posttranscriptional processes, including stem cells self-renewal and neural differentiation. Human embryonic stem cells (hESCs) and induced pluripotent stem cells (ihPSCs) show enormous potential in regenerative medicine due to their capacity to differentiate to virtually any type of cells of human body. Deciphering the role of non-coding RNAs in pluripotency, self-renewal and neural differentiation will reveal new molecular mechanisms involved in induction and maintenances of pluripotent state as well as triggering these cells toward clinically relevant cells for transplantation. In this brief review we will summarize recently published studies which reveal the role of non-coding RNAs in pluripotency and neural differentiation of hESCs and ihPSC.
Collapse
Affiliation(s)
- Dunja Lukovic
- Retina Group, Cell therapy and Regenerative Medicine, Centro Andaluz de Biología Molecular y Medicina Regenerativa Sevilla, Spain
| | - Victoria Moreno-Manzano
- Neuronal and Tissue Regeneration Lab, Centro de Investigación Príncipe Felipe Valencia, Spain
| | - Martin Klabusay
- Integrated Center of Cellular Therapy and Regenerative Medicine - International Clinical Research Center, St. Anne's University Hospital Brno Brno, Czech Republic
| | - Miodrag Stojkovic
- Spebo Medical Leskovac, Serbia ; Human Genetics Department, Faculty of Medical Sciences, University of Kragujevac Kragujevac, Serbia
| | - Shomi S Bhattacharya
- Retina Group, Cell therapy and Regenerative Medicine, Centro Andaluz de Biología Molecular y Medicina Regenerativa Sevilla, Spain
| | - Slaven Erceg
- Retina Group, Cell therapy and Regenerative Medicine, Centro Andaluz de Biología Molecular y Medicina Regenerativa Sevilla, Spain
| |
Collapse
|
6
|
Laparoscopic resections and ENCODE-guided genomics to advance surgery and oncology. Surg Endosc 2014; 28:2244-6. [PMID: 24566746 DOI: 10.1007/s00464-014-3456-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2013] [Accepted: 01/24/2014] [Indexed: 12/26/2022]
|
7
|
Ku CS, Roukos DH. From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Devices 2014; 10:1-6. [DOI: 10.1586/erd.12.63] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
8
|
Roukos DH. Integrated clinical genomics: new horizon for diagnostic and biomarker discoveries in cancer. Expert Rev Mol Diagn 2014; 13:1-4. [DOI: 10.1586/erm.12.132] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
9
|
Roukos DH. Innovation versus evidence: to trust direct-to-consumer personal genomic tests? Expert Rev Mol Diagn 2014; 11:1-4. [PMID: 21171913 DOI: 10.1586/erm.10.99] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
10
|
Dasgupta N, Xu YH, Oh S, Sun Y, Jia L, Keddache M, Grabowski GA. Gaucher disease: transcriptome analyses using microarray or mRNA sequencing in a Gba1 mutant mouse model treated with velaglucerase alfa or imiglucerase. PLoS One 2013; 8:e74912. [PMID: 24124461 PMCID: PMC3790783 DOI: 10.1371/journal.pone.0074912] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2013] [Accepted: 08/07/2013] [Indexed: 11/18/2022] Open
Abstract
Gaucher disease type 1, an inherited lysosomal storage disorder, is caused by mutations in GBA1 leading to defective glucocerebrosidase (GCase) function and consequent excess accumulation of glucosylceramide/glucosylsphingosine in visceral organs. Enzyme replacement therapy (ERT) with the biosimilars, imiglucerase (imig) or velaglucerase alfa (vela) improves/reverses the visceral disease. Comparative transcriptomic effects (microarray and mRNA-Seq) of no ERT and ERT (imig or vela) were done with liver, lung, and spleen from mice having Gba1 mutant alleles, termed D409V/null. Disease-related molecular effects, dynamic ranges, and sensitivities were compared between mRNA-Seq and microarrays and their respective analytic tools, i.e. Mixed Model ANOVA (microarray), and DESeq and edgeR (mRNA-Seq). While similar gene expression patterns were observed with both platforms, mRNA-Seq identified more differentially expressed genes (DEGs) (∼3-fold) than the microarrays. Among the three analytic tools, DESeq identified the maximum number of DEGs for all tissues and treatments. DESeq and edgeR comparisons revealed differences in DEGs identified. In 9V/null liver, spleen and lung, post-therapy transcriptomes approximated WT, were partially reverted, and had little change, respectively, and were concordant with the corresponding histological and biochemical findings. DEG overlaps were only 8–20% between mRNA-Seq and microarray, but the biological pathways were similar. Cell growth and proliferation, cell cycle, heme metabolism, and mitochondrial dysfunction were most altered with the Gaucher disease process. Imig and vela differentially affected specific disease pathways. Differential molecular responses were observed in direct transcriptome comparisons from imig- and vela-treated tissues. These results provide cross-validation for the mRNA-Seq and microarray platforms, and show differences between the molecular effects of two highly structurally similar ERT biopharmaceuticals.
Collapse
Affiliation(s)
- Nupur Dasgupta
- The Division of Human Genetics, Cincinnati Children's Hospital Research Foundation, Cincinnati, Ohio, United States of America
| | - You-Hai Xu
- The Division of Human Genetics, Cincinnati Children's Hospital Research Foundation, Cincinnati, Ohio, United States of America
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
| | - Sunghee Oh
- The Division of Human Genetics, Cincinnati Children's Hospital Research Foundation, Cincinnati, Ohio, United States of America
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
| | - Ying Sun
- The Division of Human Genetics, Cincinnati Children's Hospital Research Foundation, Cincinnati, Ohio, United States of America
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
| | - Li Jia
- CCR Bioinformatics Core, Advanced Biomedical Computing Center Frederick National Laboratory for Cancer Research, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Mehdi Keddache
- The Division of Human Genetics, Cincinnati Children's Hospital Research Foundation, Cincinnati, Ohio, United States of America
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
| | - Gregory A Grabowski
- The Division of Human Genetics, Cincinnati Children's Hospital Research Foundation, Cincinnati, Ohio, United States of America
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
- * E-mail:
| |
Collapse
|
11
|
Zografos G, Liakakos T, Roukos DH. Deep sequencing and integrative genome analysis: approaching a new class of biomarkers and therapeutic targets for breast cancer. Pharmacogenomics 2013; 14:5-8. [PMID: 23252942 DOI: 10.2217/pgs.12.189] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
12
|
Cho WCS, Roukos DH. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. Expert Rev Anticancer Ther 2013; 13:5-8. [PMID: 23259420 DOI: 10.1586/era.12.152] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
13
|
Laparoscopic total gastrectomy and gastric cancer genome architecture: lessons, cautions, and promises. Surg Endosc 2013; 27:3945-7. [DOI: 10.1007/s00464-013-2988-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2012] [Accepted: 04/18/2013] [Indexed: 01/12/2023]
|
14
|
Hottenrott C. From single protein to colorectal cancer genome landscape and network biology-based biomarkers. Surg Endosc 2013; 27:3047-8. [DOI: 10.1007/s00464-013-2852-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2012] [Accepted: 01/31/2013] [Indexed: 10/27/2022]
|
15
|
Katsios CS, Papaloukas C, Roukos DH, Baltogiannis G. Gene expression 'signature' limitations and genome architecture-based perspectives for robust cancer biomarkers. Biomark Med 2013; 7:79-82. [PMID: 23387487 DOI: 10.2217/bmm.12.102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
16
|
Dynamic imaging in medicine and network biology. Surg Endosc 2013; 27:689-90. [DOI: 10.1007/s00464-012-2467-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2012] [Accepted: 06/14/2012] [Indexed: 11/27/2022]
|
17
|
Roukos DH, Papaloukas C, Tzaphlidou M. From targeted monotherapy to combined BRAF–MEK inhibitors and integrated genome analysis for melanoma treatment. Future Oncol 2013; 9:5-8. [DOI: 10.2217/fon.12.169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Affiliation(s)
- Dimitrios H Roukos
- Centre for Biosystems & Genomic Network Medicine, Ioannina University, 45110 Ioannina, Greece
| | - Costas Papaloukas
- Centre for Biosystems & Genomic Network Medicine, Ioannina University, 45110 Ioannina, Greece
- Department of Biological Applications & Technology, University of Ioannina, Greece
| | - Margaret Tzaphlidou
- Centre for Biosystems & Genomic Network Medicine, Ioannina University, 45110 Ioannina, Greece
- Department of Medical Physics, Ioannina University, Ioannina, Greece
| |
Collapse
|
18
|
Katsios C, Ziogas DE, Roukos DH, Baltogiannis G. Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends. Expert Rev Gastroenterol Hepatol 2013; 7:5-8. [PMID: 23265143 DOI: 10.1586/egh.12.60] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
19
|
Hottenrott C. Colorectal cancer liver metastases: advances in minimally invasive surgery and genome sequencing-based discoveries. Surg Endosc 2012; 27:1848-50. [PMID: 23239302 DOI: 10.1007/s00464-012-2650-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2012] [Accepted: 10/12/2012] [Indexed: 11/29/2022]
|
20
|
Roukos DH, Ziogas DE, Papaloukas C, Baltogiannis G. Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era. Future Oncol 2012; 8:1373-6. [PMID: 23148609 DOI: 10.2217/fon.12.140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
|
21
|
GIST: advances in tyrosine kinase inhibitors enhance laparoscopic resection even in advanced disease. Surg Endosc 2012; 27:1446-7. [PMID: 23093238 DOI: 10.1007/s00464-012-2599-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2012] [Accepted: 09/10/2012] [Indexed: 10/27/2022]
|
22
|
Hottenrott C. Next-generation, genome- and mutational landscape heterogeneity-based novel biomarkers for personalized neoadjuvant treatment and laparoscopic rectal cancer resection. Surg Endosc 2012; 27:1441-3. [PMID: 23052542 DOI: 10.1007/s00464-012-2570-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Accepted: 07/24/2012] [Indexed: 11/26/2022]
|
23
|
Expanding laparoscopic gastrectomy for gastric cancer outside Korea and Japan. Surg Endosc 2012; 26:3700-1. [PMID: 22733193 DOI: 10.1007/s00464-012-2393-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2012] [Accepted: 04/28/2012] [Indexed: 12/26/2022]
|
24
|
Hottenrott C. Predictive medicine and esophageal cancer response to preoperative chemotherapy. Surg Endosc 2012; 27:347-8. [PMID: 22722770 DOI: 10.1007/s00464-012-2411-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2012] [Accepted: 05/16/2012] [Indexed: 01/13/2023]
|
25
|
Personalized medicine for laparoscopic gastrectomy in gastric cancer. Surg Endosc 2012; 26:3352-3. [PMID: 22549380 DOI: 10.1007/s00464-012-2316-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2011] [Accepted: 01/27/2012] [Indexed: 10/28/2022]
|
26
|
Hottenrott C. The long-term efficacy of laparoscopic surgery in early and advanced gastric cancer. Surg Endosc 2012; 26:3695-6. [PMID: 22538683 DOI: 10.1007/s00464-012-2275-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2011] [Accepted: 03/15/2012] [Indexed: 01/06/2023]
|
27
|
|
28
|
|
29
|
Hottenrott C. Histology classification challenges for the endoscopic treatment of early gastric cancer. Surg Endosc 2012; 26:2092-3. [PMID: 22223117 DOI: 10.1007/s00464-011-2134-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Demetriades H. HER2-Positive Gastric Cancer. Ann Surg Oncol 2011; 18 Suppl 3:S190-1. [DOI: 10.1245/s10434-011-2000-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2011] [Indexed: 11/18/2022]
|
31
|
Laparoscopic gastrectomy and impact on recurrence of gastric cancer. Surg Endosc 2011; 26:889-90. [PMID: 22011945 DOI: 10.1007/s00464-011-1965-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
32
|
Pancreatic Cancer: The Challenge of the Future in Tumorigenesis-based Prevention. World J Surg 2011; 35:2182-3. [DOI: 10.1007/s00268-011-1058-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Batsis C. Strategy for nonresponder breast cancer patients to neoadjuvant treatment. Ann Surg Oncol 2011; 18 Suppl 3:S286-7; author reply S288-9. [PMID: 21845499 DOI: 10.1245/s10434-011-1980-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Indexed: 11/18/2022]
|
34
|
Hottenrott C. Right colectomy: is it a safe and feasible totally laparoscopic approach with transvaginal specimen extraction. Surg Endosc 2011; 25:1699-700. [PMID: 20972582 DOI: 10.1007/s00464-010-1422-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Spiliotis J. Genotyping Gastric Cancer. World J Surg 2011; 35:1933-4; author reply 1935. [DOI: 10.1007/s00268-011-1005-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
36
|
Endoscopic and laparoscopic ultrasonography used to predict tumor staging and improve therapeutic decisions for upper gastrointestinal tract cancer. Surg Endosc 2011; 26:280-1. [PMID: 21789638 DOI: 10.1007/s00464-011-1847-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Hottenrott C. BRCA testing changes decision on breast cancer surgery but evidence for benefit is still scarce. Ann Surg Oncol 2011; 18 Suppl 3:S284-5. [PMID: 21761102 DOI: 10.1245/s10434-011-1935-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2011] [Indexed: 11/18/2022]
|
38
|
Hottenrott C. Preventive and therapeutic implications of positive CDH1 testing in diffuse gastric cancer. Ann Surg Oncol 2011; 18 Suppl 3:S192-3. [PMID: 21761101 DOI: 10.1245/s10434-011-1937-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2011] [Indexed: 11/18/2022]
|
39
|
Liakakos T. High ligation of inferior mesenteric artery: a standard procedure for colorectal cancer? Ann Surg Oncol 2011; 18 Suppl 3:S240-1; author reply S242-3. [PMID: 21725685 DOI: 10.1245/s10434-011-1883-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2011] [Indexed: 01/23/2023]
|
40
|
Robotic versus laparoscopic surgery for rectal cancer and cost-effectiveness analysis. Surg Endosc 2011; 25:3954-6; author reply 3957-8. [DOI: 10.1007/s00464-011-1808-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
41
|
Spiliotis J, Halkia E. Slow progress in predicting and preventing fatal gastric cancer peritoneal recurrence. Ann Surg Oncol 2011; 18 Suppl 3:S200-1; author reply S202-5. [PMID: 21691877 DOI: 10.1245/s10434-011-1851-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2011] [Indexed: 12/31/2022]
|
42
|
Roukos DH. 'Big' science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn 2011; 11:123-6. [PMID: 21405960 DOI: 10.1586/erm.11.4] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
43
|
Halkia E, Kalinoglou N. Challenges with identification of angiogenesis biomarkers in cancer. Surg Endosc 2011; 25:2769-70. [PMID: 21487885 DOI: 10.1007/s00464-011-1623-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Thoracolaparoscopic esophagectomy: further improvement in the multimodal treatment of esophageal cancer. Surg Endosc 2011; 25:3466-7. [PMID: 21487858 DOI: 10.1007/s00464-011-1691-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Liakakos T. Totally laparoscopic total gastrectomy and the challenge of esophagojejunostomy. Surg Endosc 2011; 25:3468-9; author reply 3470-1. [DOI: 10.1007/s00464-011-1692-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
46
|
Linking epidermal growth factor plasma levels with the prognosis and treatment response of colorectal cancer patients treated with a minimally invasive approach: does it have clinical utility? Surg Endosc 2011; 25:2766-7; author reply 2768. [PMID: 21416177 DOI: 10.1007/s00464-011-1622-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
|
48
|
|
49
|
Mediastinal lymphadenopathy: assessing clinical utility of EUS-FNA. Surg Endosc 2011; 25:2756-7. [PMID: 21301879 DOI: 10.1007/s00464-011-1575-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
50
|
Zografos GC, Roukos DH. Innovative biomarker development for personalized medicine in breast cancer care. Biomark Med 2011; 5:73-8. [DOI: 10.2217/bmm.10.116] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- George C Zografos
- 1st Propaedeutic Surgical Department, University of Athens, Hippocration General Hospital, Athens, Greece
| | - Dimitrios H Roukos
- Department of Surgery, Ioannina University School of Medicine, Ioannina, TK 451 10, Greece and Personalized Cancer Networks Medicine, Biobank, Ioannina University School of Medicine, Ioannina, TK 451 10, Greece
| |
Collapse
|